Security Snapshot

ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) Institutional Ownership

CUSIP: H0036K147

13F Institutional Holders and Ownership History from Q2 2020 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

112

Shares (Excl. Options)

80.64MFull value: 80,639,954 · shares · 30 Jun 2026

Price

$1.07

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Shares, par value CHF 0.08 per share
Symbol
ADCT on NYSE
All holders as of 30 Jun 2026
Q2 2026
Total 13F shares
80,639,954
Latest holder snapshot 5 signals
Total 13F value
$86,330,645
Portfolio coverage rank
0%
Share change
-2,613,957
Value change
-$26,979,234
Number of holders
112
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
148,404,655
SEC-reported price per share
$1.42
Insider filing price
$1.42
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share is tracked under CUSIP H0036K147.
  • 112 institutions reported positions in Q2 2026.
  • 10 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 118 to 112 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $312.9MFull value: $312,902,534 · USD · 31 Mar 2026
    to
    $86.33MFull value: $86,330,645 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 112 institutions filings for Q2 2026.

Open SEC evidence

Security key

H0036K147

13F reference period

Q2 2026

13F holders

112

13D/G owners

10

CIK / CUSIP context first

Open Q2 2026 holders ADCT full holder history ADC Therapeutics SA SEC filings ADC Therapeutics SA company facts ADC Therapeutics SA insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
10
Security
ADCT
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Bain Capital Life Sciences Opportunities IV, L.P. 10% $18,087,262 14,825,625 Bain Capital Life Sciences Opportunities IV, L.P. 22 Oct 2026
Redmile Group, LLC 9.9% 0% $47,690,576 +$92,422 12,717,487 +0.19% Redmile Group, LLC 20 Apr 2026
Nantahala Capital Management, LLC 9.7% $15,900,777 12,326,184 Nantahala Capital Management, LLC 30 Jun 2026
TCG Crossover GP II, LLC 9.2% $42,143,648 11,390,175 TCG Crossover GP II, LLC 27 Oct 2025
HPWH TH AG 9.6% $14,291,858 9,788,944 Dr. Hans-Peter Wild 15 May 2025
Prosight Management, LP 6.8% +17% $31,366,151 +$4,743,267 8,477,338 +18% Prosight Management, LP 31 Dec 2025
BlackRock, Inc. 5.4% +8% $7,341,291 +$2,081,761 6,857,815 +40% BlackRock, Inc. 30 Jun 2026
Point72 Asset Management, L.P. 4% -43% $18,554,083 -$10,422,190 5,014,617 -36% Point72 Asset Management, L.P. 31 Dec 2025
Oaktree Capital Group Holdings GP, LLC 4.1% $18,693,764 4,673,441 Oaktree Fund Administration, LLC 30 Sep 2025
ORBIMED ADVISORS LLC 2.6% -25% $11,953,949 -$765,959 3,230,797 -6% ORBIMED CAPITAL LLC 31 Dec 2025
As of 30 Jun 2026, 112 institutional investors reported holding
80.64MFull value: 80,639,954 · shares · 30 Jun 2026
shares of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT). This represents 54% of the company’s total
148.4MFull value: 148,404,655 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
51%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Nantahala Capital Management, LLC 8.3% 12,326,184 +120% 0.8% $13,189,017
Redmile Group, LLC 7.8% 11,526,710 -25% 0.83% $12,333,580
TCG Crossover Management, LLC 7.7% 11,390,175 0% 0.29% $12,187,487
Prosight Management, LP 5.3% 7,824,749 -5.7% 1.4% $8,372,481
BlackRock, Inc. 4.7% 7,020,093 +12% 0% $7,511,500
Point72 Asset Management, L.P. 2.5% 3,649,144 +7.9% 0.01% $3,904,584
MORGAN STANLEY 2.1% 3,051,173 -20% 0% $3,264,755
MILLENNIUM MANAGEMENT LLC 2% 2,899,535 -7% 0% $3,102,502
CITADEL ADVISORS LLC 1.4% 2,053,316 +414% 0% $2,197,048
GOLDMAN SACHS GROUP INC 1.3% 1,914,424 +16% 0% $2,048,434
STATE STREET CORP 1.1% 1,685,836 +7.6% 0% $1,803,845
GEODE CAPITAL MANAGEMENT, LLC 0.97% 1,445,546 +20% 0% $1,546,733
BANK OF AMERICA CORP /DE/ 0.87% 1,288,206 -2.8% 0% $1,378,381
VANGUARD PORTFOLIO MANAGEMENT LLC 0.6% 897,092 -13% 0% $959,888
TWO SIGMA INVESTMENTS, LP 0.52% 773,414 +16% 0% $827,553
Blue Owl Capital Holdings LP 0.49% 733,568 0% 0.12% $784,918
D. E. Shaw & Co., Inc. 0.48% 719,320 +196% 0% $769,672
Opaleye Management Inc. 0.47% 700,000 0.07% $749,000
AQR CAPITAL MANAGEMENT LLC 0.44% 658,125 +177% 0% $704,193
BNP PARIBAS FINANCIAL MARKETS 0.44% 652,849 0% 0% $698,548
NORTHERN TRUST CORP 0.4% 594,025 +7.6% 0% $635,607
PLATINUM INVESTMENT MANAGEMENT LTD 0.39% 581,609 -41% 0.15% $622,322
PANAGORA ASSET MANAGEMENT INC 0.39% 572,816 -17% 0% $612,913
UBS Group AG 0.35% 520,293 +13% 0% $556,714
SCHRODER INVESTMENT MANAGEMENT GROUP 0.28% 418,782 0% 0% $431,345

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
26
Headline period
Q2 2026
Rows shown
1-25 of 26
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 10,493,594 $12,807,664 +$6,294,053 $1.22 38
2026 Q2 80,639,954 $86,330,645 -$26,979,234 $1.07 112
2026 Q1 83,513,765 $312,902,534 +$4,946,064 $3.75 118
2025 Q4 82,866,392 $292,847,655 +$51,266,809 $3.53 115
2025 Q3 68,158,412 $272,625,712 -$9,526,921 $4.00 105
2025 Q2 67,952,003 $182,114,158 +$35,606,077 $2.68 84
2025 Q1 54,846,167 $77,332,587 -$2,528,133 $1.41 82
2024 Q4 56,494,277 $112,422,732 -$3,041,138 $1.99 82
2024 Q3 54,883,537 $172,881,709 +$3,394,419 $3.15 76
2024 Q2 51,801,951 $163,693,841 +$51,364,315 $3.16 73
2024 Q1 34,683,534 $155,728,721 +$7,168,355 $4.49 36
2023 Q4 33,953,461 $56,361,695 -$3,915,509 $1.66 36
2023 Q3 39,458,503 $35,390,528 -$10,272,333 $0.90 40
2023 Q2 45,357,348 $97,515,460 -$1,939,928 $2.15 55
2023 Q1 46,611,135 $90,890,151 +$6,156,453 $1.95 57
2022 Q4 38,834,584 $149,117,927 +$3,712,534 $3.84 59
2022 Q3 36,621,247 $176,523,672 +$9,038,590 $4.82 60
2022 Q2 34,475,113 $274,062,429 +$4,571,679 $7.95 52
2022 Q1 34,123,674 $501,279,862 +$2,970,760 $14.69 44
2021 Q4 33,799,357 $682,750,000 +$19,180,842 $20.20 50
2021 Q3 32,792,604 $890,647,136 -$45,594,727 $27.16 51
2021 Q2 33,533,099 $816,251,800 +$17,173,667 $24.35 53
2021 Q1 32,826,058 $801,283,858 +$19,636,706 $24.41 55
2020 Q4 32,141,073 $1,028,835,000 +$31,200,598 $32.01 51
2020 Q3 28,226,306 $921,776,783 +$216,837,760 $32.99 51
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .